Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review
- PMID: 33767108
- PMCID: PMC8191753
- DOI: 10.14309/ajg.0000000000001222
Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review
Abstract
Introduction: Constipation is commonly treated with over-the-counter (OTC) products whose efficacy and safety remain unclear. We performed a systematic review of OTC therapies for chronic constipation and provide evidence-based recommendations.
Methods: We searched PubMed and Embase for randomized controlled trials of ≥4-week duration that evaluated OTC preparations between 2004 and 2020. Studies were scored using the US Preventive Services Task Force criteria (0-5 scale) including randomization, blinding, and withdrawals. The strengths of evidence were adjudicated within each therapeutic category, and recommendations were graded (A, B, C, D, and I) based on the level of evidence (level I, good; II, fair; or III, poor).
Results: Of 1,297 studies identified, 41 met the inclusion criteria. There was good evidence (grade A recommendation) for the use of the osmotic laxative polyethylene glycol (PEG) and the stimulant senna; moderate evidence (grade B) for psyllium, SupraFiber, magnesium salts, stimulants (bisacodyl and sodium picosulfate), fruit-based laxatives (kiwi, mango, prunes, and ficus), and yogurt with galacto-oligosaccharide/prunes/linseed oil; and insufficient evidence (grade I) for polydextrose, inulin, and fructo-oligosaccharide. Diarrhea, nausea, bloating, and abdominal pain were common adverse events, but no serious adverse events were reported.
Discussion: The spectrum of OTC products has increased and quality of evidence has improved, but methodological issues including variability in study design, primary outcome measures, trial duration, and small sample sizes remain. We found good evidence to recommend polyethylene glycol or senna as first-line laxatives and moderate evidence supporting fiber supplements, fruits, stimulant laxatives, and magnesium-based products. For others, further validation with more rigorously designed studies is warranted.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Conflict of interest statement
Figures
Similar articles
-
Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).Evid Based Child Health. 2013 Jan;8(1):57-109. doi: 10.1002/ebch.1893. Evid Based Child Health. 2013. PMID: 23878124 Review.
-
Evidence-based treatment recommendations for OTC management of chronic constipation.J Am Assoc Nurse Pract. 2022 Sep 1;34(9):1041-1044. doi: 10.1097/JXX.0000000000000760. J Am Assoc Nurse Pract. 2022. PMID: 35943487 Free PMC article.
-
OTC laxative use of sodium picosulfate â results of a pharmacy-based patient survey (cohort study).Int J Clin Pharmacol Ther. 2008 Feb;46(2):89-95. doi: 10.5414/cpp46089. Int J Clin Pharmacol Ther. 2008. PMID: 18218289
-
Long term treatment with stimulant laxatives - clinical evidence for effectiveness and safety?Scand J Gastroenterol. 2019 Jan;54(1):27-34. doi: 10.1080/00365521.2018.1563806. Epub 2019 Jan 31. Scand J Gastroenterol. 2019. PMID: 30700194 Review.
-
Management of chronic constipation in patients with diabetes mellitus.Indian J Gastroenterol. 2017 Jan;36(1):11-22. doi: 10.1007/s12664-016-0724-2. Epub 2016 Dec 17. Indian J Gastroenterol. 2017. PMID: 27987136 Review.
Cited by
-
Effects of Ethanol Extract from Senna Leaf (EESL) on Inflammation and Oxidative Stress in Mice: A Non-targeted Metabolomic Study.Endocr Metab Immune Disord Drug Targets. 2025;25(9):695-709. doi: 10.2174/0118715303325372241014152811. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39449343 Free PMC article.
-
The Associations Between Life's Essential 8 and Diarrhea and Constipation: Results From the 2005-2010 National Health and Nutrition Examination Survey.Clin Transl Gastroenterol. 2025 Feb 1;16(2):e00801. doi: 10.14309/ctg.0000000000000801. Clin Transl Gastroenterol. 2025. PMID: 39692309 Free PMC article.
-
Clinical efficacy of non-pharmacological treatment of functional constipation: a systematic review and network meta-analysis.Front Cell Infect Microbiol. 2025 May 29;15:1565801. doi: 10.3389/fcimb.2025.1565801. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40510802 Free PMC article.
-
Effects of Three Microbiome-Based Therapies on Loperamide-Induced Constipation in Mice by Restoring Intestinal Motility and Modulating the Intestinal Microbiota.Probiotics Antimicrob Proteins. 2025 Aug 27. doi: 10.1007/s12602-025-10732-x. Online ahead of print. Probiotics Antimicrob Proteins. 2025. PMID: 40864418
-
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.Gastroenterology. 2023 Jun;164(7):1086-1106. doi: 10.1053/j.gastro.2023.03.214. Gastroenterology. 2023. PMID: 37211380 Free PMC article.
References
-
- Pare P, Ferrazzi S, Thompson WG, et al. . An epidemiological survey of constipation in Canada: Definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96:3130–7. - PubMed
-
- Higgins PD, Johanson JF. Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol 2004;99(4):750–9. - PubMed
-
- Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis. Am J Gastroenterol 2011;106:1582–91. - PubMed
-
- Cai Q, Buono JL, Spalding WM, et al. . Healthcare costs among patients with chronic constipation: A retrospective claims analysis in a commercially insured population. J Med Econ 2014;17:148–58. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous